S.Korea's Celltrion says COVID-19 drug shows 100-fold reduction in viral load
SEOUL, June 1 (Reuters) - South Korea's Celltrion Inc
068270.KS said on Monday its experimental treatment of
COVID-19 demonstrated a 100-fold reduction in viral load of the
disease in animal testing.
The pharmaceutical company said the first in-human clinical
trials of the treatment are set to start in July.
(Reporting by Joyce Lee; Editing by Himani Sarkar)
((jungyoon.lee@tr.com; +82 2 6936 1467;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap